PharmaEssentia Corporation has received approval from Taiwan’s Ministry of Health and Welfare for Besremi (ropeginterferon alfa-2b) for the treatment of adult patients with essential thrombocythemia (ET).

• Clinical Data: Approval was supported by results from the Phase 3 SURPASS-ET study, which showed a 42.9% durable clinical response rate for Besremi compared with 6.0% for anagrelide.
• Patient Population: The treatment is indicated for adult patients with high-risk ET who are resistant or intolerant to hydroxyurea.
• Regulatory Status: A supplemental Biologics License Application (sBLA) for ET is currently under review by the US Food and Drug Administration.

This summary is based on a press release issued by PharmaEssentia Corporation via BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.